Stocks · News reference
HC Wainwright has lowered its price target for Aardvark Therapeutics from $4.00 to $2.00 while maintaining a Neutral rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The U.S. Food and Drug Administration has lifted the clinical hold on Aardvark Therapeutics' investigational new drug application for ARD-101, intended for treating hyperphagia in Prader-Willi Syndrome.
Aardvark Therapeutics released exploratory efficacy and safety data from its previously terminated Phase 3 HERO and open-label extension trials for ARD-101.
Filed: 2026-10-23 AccNo: 0001193125-26-429509 Size: 11 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits